These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 11320399)
1. Alpha1-antitrypsin deficiency: a position statement of the Canadian Thoracic Society. Abboud RT; Ford GT; Chapman KR; Can Respir J; 2001; 8(2):81-8. PubMed ID: 11320399 [TBL] [Abstract][Full Text] [Related]
2. Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome? Abboud RT; Ford GT; Chapman KR Treat Respir Med; 2005; 4(1):1-8. PubMed ID: 15725045 [TBL] [Abstract][Full Text] [Related]
3. Indications for active case searches and intravenous alpha-1 antitrypsin treatment for patients with alpha-1 antitrypsin deficiency chronic pulmonary obstructive disease: an update. Casas F; Blanco I; Martínez MT; Bustamante A; Miravitlles M; Cadenas S; Hernández JM; Lázaro L; Rodríguez E; Rodríguez-Frías F; Torres M; Lara B Arch Bronconeumol; 2015 Apr; 51(4):185-92. PubMed ID: 25027067 [TBL] [Abstract][Full Text] [Related]
4. Augmentation Therapy for Severe Alpha-1 Antitrypsin Deficiency Improves Survival and Is Decoupled from Spirometric Decline-A Multinational Registry Analysis. Fraughen DD; Ghosh AJ; Hobbs BD; Funk GC; Meischl T; Clarenbach CF; Sievi NA; Schmid-Scherzer K; McElvaney OJ; Murphy MP; Roche AD; Clarke L; Strand M; Vafai-Tabrizi F; Kelly G; Gunaratnam C; Carroll TP; McElvaney NG Am J Respir Crit Care Med; 2023 Nov; 208(9):964-974. PubMed ID: 37624745 [No Abstract] [Full Text] [Related]
5. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Seersholm N; Wencker M; Banik N; Viskum K; Dirksen A; Kok-Jensen A; Konietzko N Eur Respir J; 1997 Oct; 10(10):2260-3. PubMed ID: 9387950 [TBL] [Abstract][Full Text] [Related]
6. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG; Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936 [TBL] [Abstract][Full Text] [Related]
10. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med; 1998 Jul; 158(1):49-59. PubMed ID: 9655706 [TBL] [Abstract][Full Text] [Related]
11. Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 years. Piitulainen E; Mostafavi B; Tanash HA Int J Chron Obstruct Pulmon Dis; 2017; 12():495-500. PubMed ID: 28203073 [TBL] [Abstract][Full Text] [Related]
12. Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry. Rahaghi FF; Monk R; Ramakrishnan V; Beiko T; Strange C Int J Chron Obstruct Pulmon Dis; 2020; 15():3193-3199. PubMed ID: 33299307 [TBL] [Abstract][Full Text] [Related]
13. α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy. Campos MA; Lascano J Ther Adv Respir Dis; 2014 Oct; 8(5):150-61. PubMed ID: 25013223 [TBL] [Abstract][Full Text] [Related]
14. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence. Rahaghi FF; Miravitlles M Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837 [TBL] [Abstract][Full Text] [Related]
15. Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ; 1997; 75(5):397-415. PubMed ID: 9447774 [TBL] [Abstract][Full Text] [Related]
16. Clinical utility of alpha-1 proteinase inhibitor in the management of adult patients with severe alpha-1 antitrypsin deficiency: a review of the current literature. Parr DG; Lara B Drug Des Devel Ther; 2017; 11():2149-2162. PubMed ID: 28769553 [TBL] [Abstract][Full Text] [Related]
17. Heritability of lung function in severe alpha-1 antitrypsin deficiency. DeMeo DL; Campbell EJ; Brantly ML; Barker AF; Eden E; McElvaney NG; Rennard SI; Stocks JM; Stoller JK; Strange C; Turino G; Sandhaus RA; Silverman EK Hum Hered; 2009; 67(1):38-45. PubMed ID: 18931508 [TBL] [Abstract][Full Text] [Related]
18. Diagnosis and treatment of lung disease associated with alpha one-antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand. Dummer J; Dobler CC; Holmes M; Chambers D; Yang IA; Parkin L; Smith S; Wark P; Dev A; Hodge S; Dabscheck E; Gooi J; Samuel S; Knowles S; Holland AE Respirology; 2020 Mar; 25(3):321-335. PubMed ID: 32030868 [TBL] [Abstract][Full Text] [Related]
19. Alpha1-antitrypsin replacement therapy controls fibromyalgia symptoms in 2 patients with PI ZZ alpha1-antitrypsin deficiency. Blanco I; Canto H; de Serres FJ; Fernandez-Bustillo E; Rodríguez MC J Rheumatol; 2004 Oct; 31(10):2082-5. PubMed ID: 15468381 [TBL] [Abstract][Full Text] [Related]